INKT Stock Summary and Trading Ideas (Mink Therapeutics | NASDAQ:INKT)

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.

Mink Therapeutics trades on the NASDAQ stock market under the symbol INKT.

As of November 11, 2026, INKT stock price climbed to $10.22 with 14,671 million shares trading.

INKT has a market cap of $52.17 million. This is considered a Micro Cap stock.

In the last 3 years, INKT traded as high as $76.00 and as low as $.46.

The top ETF exchange traded funds that INKT belongs to (by Net Assets): VTI, VXF, IWC.

INKT has underperformed the market in the last year with a price return of -25.8% while the SPY ETF gained +12.6%. INKT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -6.6% and -3.8%, respectively, while the SPY returned -1.5% and -1.3%, respectively.

INKT support price is $9.31 and resistance is $10.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INKT shares will trade within this expected range on the day.